Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 4/20 | 0.53 |
| ▸ | FPR3 | P25089 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12810103 | 0.84 | FPR3 (0.49) | HCRTR1FPR3FPR2HCRTR2PRMT5 | |
| SCHEMBL889104 | 0.81 | PRMT5 (0.46) | HCRTR1FPR3FPR2HCRTR2PRMT5 | |
| SCHEMBL7204445 | 0.81 | PRMT5 (0.46) | HCRTR1FPR3FPR2HCRTR2PRMT5 | |
| SCHEMBL23747089 | 0.81 | PRMT5 (0.42) | HCRTR1FPR3FPR2HCRTR2PRMT5 | |
| SCHEMBL12810180 | 0.81 | FPR3 (0.54) | FPR3FPR2PRMT5KMT2AUSP30 | |
| SCHEMBL12810167 | 0.81 | PRMT5 (0.45) | HCRTR1HCRTR2PRMT5CHEK2GPR119 | |
| SCHEMBL888999 | 0.80 | PRMT5 (0.40) | HCRTR1HCRTR2PRMT5CHEK2GPR119 | |
| SCHEMBL12810003 | 0.80 | L3MBTL1 (0.57) | FPR3FPR2PRMT5KMT2ACHEK2 | |
| SCHEMBL1598677 | 0.80 | FPR3 (0.53) | HCRTR1FPR3FPR2HCRTR2PRMT5 | |
| SCHEMBL1598674 | 0.80 | FPR3 (0.53) | HCRTR1FPR3FPR2HCRTR2PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011031934-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | HCRTR1 3277/4885FPR3 3154/4885FPR2 4049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.